Company Continues Tests On Nasal Bird Flu Vaccine

Tag it:

DelSite Biotechnologies has recently begun animal toxicology studies of its GelVac nasal powder influenza vaccine that includes a bird flu antigen.

Toxicology studies are an important step during the vaccine development and will assess the safety of the vaccine in animals.

The toxicology studies are being conducted at a contract research organization, using study protocols that have been reviewed by the Food and Drug Administration (FDA).

The GelVac nasal powder platform is an in-situ gelling powder formulation based on the company's polymer technologies.

Tag it:

Tags:

Click to add your tags...,

or Close

Comments (0) >>

Write comment

You must be logged in to a comment. Please register if you do not have an account yet.